ReviewFEBS letters2010
The conundrum of inhibitory signaling by ITAM-containing immunoreceptors: potential molecular mechanisms.
Review in FEBS letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Identification of a novel, expressed, alternatively spliced FCER1G protein that inhibits receptor function.Frontiers in immunology · 2026Article
- Early events in TCR signaling - the evolving role of ITAMs.Frontiers in immunology · 2025Review
- Immunoregulatory Property of C-Type Lectin-Like Receptors in Fibrosing Interstitial Lung Diseases.International journal of molecular sciences · 2020Review
- The MS4A family: counting past 1, 2 and 3.Immunology and cell biology · 2016Review
- Multigene families of immunoglobulin domain-containing innate immune receptors in zebrafish: deciphering the differences.Developmental and comparative immunology · 2014Review
- The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.Haematologica · 2014Review
- Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Phosphatase regulation of immunoreceptor signaling in T cells, B cells and mast cells.Current opinion in immunology · 2013Review
- Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.Critical care (London, England) · 2012Review
- Human lupus serum induces neutrophil-mediated organ damage in mice that is enabled by Mac-1 deficiency.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities.Antioxidants & redox signaling · 2012Review
- Stimulation of unprimed macrophages with immune complexes triggers a low output of nitric oxide by calcium-dependent neuronal nitric-oxide synthase.The Journal of biological chemistry · 2012Article
- The adaptor protein SAP directly associates with CD3ζ chain and regulates T cell receptor signaling.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Immunoreceptor signals must be appropriately transduced and regulated to achieve effective immunity while controlling inflammation and autoimmunity. It is generally held that these processes are mediated by the interplay of distinct activating and inhibitory receptors via conserved activating (ITAM) and inhibitory (ITIM) signaling motifs. However, recent evidence indicates that under certain conditions incomplete phosphorylation of ITAM tyrosines leads to inhibitory signaling. This new regulatory function of ITAMs has been termed ITAMi (inhibitory ITAM). Here we discuss the potential molecular mechanisms of inhibitory signaling by ITAM-containing receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.